Enliven Treateutics(ELVN),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

ELVN Enliven Treateutics

Market Closed 12-19 16:00:00 EST

16.87

+0.19

+1.14%

盘后16.87

+0.000.00%

18:07 EST

High17.15	Low16.61	Vol1.22M
Open16.71	D1 Closing16.68	Amplitude3.27%
Mkt Cap1.00B	Tradable Cap590.44M	Total Shares59.35M
T/O20.62M	T/O Rate3.50%	Tradable Shares35.00M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"ELVN","market":"US","secType":"STK","nameCN":"Enliven Treateutics","latestPrice":16.87,"timestamp":1766178000000,"preClose":16.68,"halted":0,"volume":1223311,"hourTrading":{"tag":"盘后","latestPrice":16.87,"preClose":16.87,"latestTime":"18:07 EST","volume":230023,"amount":3880426.3543,"timestamp":1766185630208},"delay":0,"floatShares":34999600,"shares":59347317,"eps":-1.814739,"marketStatus":"Market Closed","change":0.19,"latestTime":"12-19 16:00:00 EST","open":16.71,"high":17.15,"low":16.605,"amount":20619357.083447997,"amplitude":0.032674,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-1.814739,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1766394000000},"marketStatusCode":7,"adr":0,"listingDate":1583985600000,"exchange":"NASDAQ","adjPreClose":16.68,"preHourTrading":{"tag":"盘前","latestPrice":16.78,"preClose":16.68,"latestTime":"09:26 EST","volume":5618,"amount":93616.099182,"timestamp":1766154386676},"postHourTrading":{"tag":"盘后","latestPrice":16.87,"preClose":16.87,"latestTime":"18:07 EST","volume":230023,"amount":3880426.3543,"timestamp":1766185630208},"volumeRatio":1.0565611398681056,"impliedVol":0.4823,"impliedVolPercentile":0.36},"requestUrl":"/m/hq/s/ELVN/tweets","defaultTab":"tweets","newsList":[{"id":"2591125666","title":"Enliven Therapeutics (ELVN): Taking Stock of Valuation After Leadership Shift and Upcoming ELVN-001 Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2591125666","media":"Simply Wall St.","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591125666?lang=en_us&edition=fundamental","pubTime":"2025-12-15 14:18","pubTimestamp":1765779487,"startTime":"0","endTime":"0","summary":"Enliven Therapeutics (ELVN) just reshuffled its top ranks, naming industry veteran Richard Fair as CEO, President, and board member, while co founder Sam Kintz shifts to Head of Pipeline to focus on R and D.\nSee our latest analysis for Enliven Therapeutics.\nThe leadership shake up lands after a rough stretch for the stock, with a 7 day share price return of minus 22.7 percent and a 1 year total shareholder return of minus 27.17 percent. This suggests momentum has been fading despite the late...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-elvn/enliven-therapeutics/news/enliven-therapeutics-elvn-taking-stock-of-valuation-after-le","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-elvn/enliven-therapeutics/news/enliven-therapeutics-elvn-taking-stock-of-valuation-after-le","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4139","BK4007","ELVN","BK4539","LENZ"],"gpt_icon":0},{"id":"2591728682","title":"Enliven Therapeutics Files Initial Beneficial Ownership Statement for President and CEO Richard A. Fair","url":"https://stock-news.laohu8.com/highlight/detail?id=2591728682","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591728682?lang=en_us&edition=fundamental","pubTime":"2025-12-13 07:30","pubTimestamp":1765582248,"startTime":"0","endTime":"0","summary":"Enliven Therapeutics Inc. has filed an initial statement of beneficial ownership with the U.S. Securities and Exchange Commission. The filing identifies Richard A. Fair as the beneficial owner, serving as President, CEO, and Director of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Enliven Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on December 12, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251212:nNDL5cTZTs:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"Enliven Therapeutics Files Initial Beneficial Ownership Statement for President and CEO Richard A. Fair","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ELVN","BK4007"],"gpt_icon":0},{"id":"2590557541","title":"Enliven Therapeutics Grants CEO Richard Fair Stock Option Inducement Package","url":"https://stock-news.laohu8.com/highlight/detail?id=2590557541","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590557541?lang=en_us&edition=fundamental","pubTime":"2025-12-12 05:22","pubTimestamp":1765488151,"startTime":"0","endTime":"0","summary":"Enliven Therapeutics Inc. has granted an inducement stock option to Richard Fair, the company's new President and Chief Executive Officer. Fair received an option to purchase 875,000 shares of Enliven's common stock at an exercise price of $18.77 per share, which was the closing price on the grant date. The option will vest with 25% of the shares vesting on the first anniversary of the grant, and the remaining shares vesting in equal monthly installments over the following three years, contingent on continued service.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Enliven Therapeutics Inc. published the original content used to generate this news brief via PR Newswire  on December 11, 2025, and is solely responsible for the information","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251211:nNDL7SYxdz:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","ELVN"],"gpt_icon":0},{"id":"2590541328","title":"Enliven Therapeutics Reports Inducement Grants as Permitted by the Nasdaq Listing Rules","url":"https://stock-news.laohu8.com/highlight/detail?id=2590541328","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590541328?lang=en_us&edition=fundamental","pubTime":"2025-12-12 05:22","pubTimestamp":1765488140,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251211:nTUAJLSL9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","ELVN"],"gpt_icon":0},{"id":"2590051139","title":"BRIEF-Enliven Therapeutics Announces New CEO To Drive Next Phase Of Development","url":"https://stock-news.laohu8.com/highlight/detail?id=2590051139","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590051139?lang=en_us&edition=fundamental","pubTime":"2025-12-11 22:02","pubTimestamp":1765461755,"startTime":"0","endTime":"0","summary":"BRIEF-Enliven Therapeutics Announces New CEO To Drive Next Phase Of DevelopmentDec 11 (Reuters) - Enliven Therapeutics Inc ELVN.O:ENLIVEN THERAPEUTICS ANNOUNCES NEW CEO TO DRIVE NEXT PHASE OF DEVELOPM","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251211:nTUA71MF5K:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ELVN","BK4007"],"gpt_icon":0},{"id":"2590113555","title":"Enliven Therapeutics Names Rick Fair CEO","url":"https://stock-news.laohu8.com/highlight/detail?id=2590113555","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590113555?lang=en_us&edition=fundamental","pubTime":"2025-12-11 22:01","pubTimestamp":1765461686,"startTime":"0","endTime":"0","summary":"Enliven Therapeutics Inc. has appointed Rick Fair as Chief Executive Officer and member of the Board of Directors, effective December 11, 2025. Co-founder and former CEO Sam Kintz will transition to the role of Head of Pipeline.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Enliven Therapeutics Inc. published the original content used to generate this news brief via PR Newswire  on December 11, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251211:nNDLbxthbl:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","ELVN"],"gpt_icon":0},{"id":"2590828511","title":"Enliven Therapeutics Inc - Rick Fair Appointed CEO and Board Member Effective Dec 11, 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2590828511","media":"THOMSON REUTERS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590828511?lang=en_us&edition=fundamental","pubTime":"2025-12-11 22:00","pubTimestamp":1765461606,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251211:nTUA71MF5K:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ELVN","BK4007"],"gpt_icon":0},{"id":"2590511846","title":"Enliven Therapeutics Announces New CEO to Drive Next Phase of Development","url":"https://stock-news.laohu8.com/highlight/detail?id=2590511846","media":"THOMSON REUTERS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590511846?lang=en_us&edition=fundamental","pubTime":"2025-12-11 22:00","pubTimestamp":1765461606,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251211:nTUA71MF5K:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ELVN","BK4007"],"gpt_icon":0},{"id":"2590511844","title":"Enliven Therapeutics Inc - Rick Fair Joins Enliven as CEO","url":"https://stock-news.laohu8.com/highlight/detail?id=2590511844","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590511844?lang=en_us&edition=fundamental","pubTime":"2025-12-11 22:00","pubTimestamp":1765461606,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251211:nTUA71MF5K:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","ELVN"],"gpt_icon":0},{"id":"2590555265","title":"Enliven Therapeutics COO Anish Patel Reports Disposal of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2590555265","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590555265?lang=en_us&edition=fundamental","pubTime":"2025-12-11 06:13","pubTimestamp":1765404835,"startTime":"0","endTime":"0","summary":"Anish Patel, Chief Operating Officer of Enliven Therapeutics Inc., has reported a disposal of common shares of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Enliven Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on December 10, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251210:nNDL5kS28G:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Enliven Therapeutics COO Anish Patel Reports Disposal of Common Shares","news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","ELVN"],"gpt_icon":0},{"id":"2590717346","title":"Tiny Biotech Terns Takes Aim At Novartis' Leukemia Blockbuster","url":"https://stock-news.laohu8.com/highlight/detail?id=2590717346","media":"Benzinga_recent_news","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590717346?lang=en_us&edition=fundamental","pubTime":"2025-12-09 20:51","pubTimestamp":1765284660,"startTime":"0","endTime":"0","summary":"Terns Pharma presented positive data from ongoing CARDINAL trial of TERN-701 in CML patients, showing high MMR rates and good safety profile.","market":"hk","thumbnail":"https://cdn.benzinga.com/files/images/story/2025/12/09/cancer_0.jpeg?optimize=medium&dpr=2&auto=webp&width=120","type":0,"news_type":0,"thumbnails":["https://cdn.benzinga.com/files/images/story/2025/12/09/cancer_0.jpeg?optimize=medium&dpr=2&auto=webp&width=120"],"rights":{"source":"benzinga_recent_news","url":"https://www.benzinga.com/analyst-stock-ratings/analyst-color/25/12/49277005/tiny-biotech-terns-takes-aim-at-novartis-leukemia-blockbuster","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/analyst-stock-ratings/analyst-color/25/12/49277005/tiny-biotech-terns-takes-aim-at-novartis-leukemia-blockbuster","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"benzinga_recent_news","symbols":["ELVN","LU0320765489.SGD","NVS","TERN","IE0002141913.USD","LU0070302665.USD","IE00BJJMRZ35.SGD","IE0009355771.USD","IE00BFTCPJ56.SGD","LU0211331839.USD","BK4532","IE00BJT1NW94.SGD","BK4578","BK4007","IE00B4R5TH58.HKD","IE00B2B36J28.USD","BK4585","LU0208291251.USD","BK4588"],"gpt_icon":0},{"id":"2589018865","title":"Enliven Therapeutics (ELVN): Assessing Valuation After a Recent 13% Share Price Rebound","url":"https://stock-news.laohu8.com/highlight/detail?id=2589018865","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589018865?lang=en_us&edition=fundamental","pubTime":"2025-12-05 12:42","pubTimestamp":1764909739,"startTime":"0","endTime":"0","summary":"Enliven Therapeutics (ELVN) has quietly outperformed the broader biotech space over the past month, climbing about 13% as investors revisit its early stage oncology pipeline and the cash runway behind it.\nSee our latest analysis for Enliven Therapeutics.\nThat latest move takes Enliven’s share price to about $21.40, and while the 1 month share price return of roughly 12.6% contrasts with a still negative year to date share price return, it suggests momentum may be starting to rebuild as...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-elvn/enliven-therapeutics/news/enliven-therapeutics-elvn-assessing-valuation-after-a-recent","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-elvn/enliven-therapeutics/news/enliven-therapeutics-elvn-assessing-valuation-after-a-recent","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4007","LENZ","BK4139","BK4539","ELVN"],"gpt_icon":0},{"id":"2585218481","title":"Enliven Therapeutics Chief Scientific Officer Joseph P. Lyssikatos Reports Sale of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2585218481","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585218481?lang=en_us&edition=fundamental","pubTime":"2025-11-22 06:28","pubTimestamp":1763764117,"startTime":"0","endTime":"0","summary":"Joseph P. Lyssikatos, Chief Scientific Officer of Enliven Therapeutics Inc., has reported a disposal of common shares of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Enliven Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on November 21, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251121:nNDL9sW34q:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"Enliven Therapeutics Chief Scientific Officer Joseph P. Lyssikatos Reports Sale of Common Shares","news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","ELVN"],"gpt_icon":0},{"id":"2584089974","title":"Enliven Therapeutics CEO Samuel Kintz Reports Disposal of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2584089974","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584089974?lang=en_us&edition=fundamental","pubTime":"2025-11-20 07:45","pubTimestamp":1763595949,"startTime":"0","endTime":"0","summary":"Samuel Kintz, President and CEO of Enliven Therapeutics Inc., has reported a disposal of common shares of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Enliven Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on November 19, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251119:nNDLbH7SWD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Enliven Therapeutics CEO Samuel Kintz Reports Disposal of Common Shares","news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ELVN","BK4007"],"gpt_icon":0},{"id":"2583221589","title":"Enliven Therapeutics COO Anish Patel Reports Sale of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2583221589","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583221589?lang=en_us&edition=fundamental","pubTime":"2025-11-13 06:34","pubTimestamp":1762986882,"startTime":"0","endTime":"0","summary":"Anish Patel, Chief Operating Officer of Enliven Therapeutics Inc., reported a disposal of common shares of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Enliven Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on November 12, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251112:nNDL336f6Y:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Enliven Therapeutics COO Anish Patel Reports Sale of Common Shares","news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","ELVN"],"gpt_icon":0},{"id":"2583588147","title":"Enliven Therapeutics reports third quarter net loss of $20.1 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2583588147","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583588147?lang=en_us&edition=fundamental","pubTime":"2025-11-13 05:08","pubTimestamp":1762981682,"startTime":"0","endTime":"0","summary":"Enliven Therapeutics Inc. reported a net loss of $20.1 million for the third quarter of 2025, compared to a net loss of $23.2 million in the same period of 2024. Research and development expenses were $18.2 million, down from $21.3 million in the prior year's quarter. General and administrative expenses totaled $6.9 million, up from $5.8 million in the third quarter of 2024. As of September 30, 2025, the company held $477.6 million in cash, cash equivalents, and marketable securities, expected to provide a cash runway into the first half of 2029. During the quarter, Enliven completed enrollment of the randomized Phase 1b cohorts of the ENABLE trial of ELVN-001 in CML and remains on track to initiate a Phase 3 pivotal trial in 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251112:nNDL6Vfsn8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ELVN","BK4007"],"gpt_icon":0},{"id":"2583588766","title":"Enliven Therapeutics: Remains on Track to Initiate Phase 3 Pivotal Trial of Elvn-001 in 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2583588766","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583588766?lang=en_us&edition=fundamental","pubTime":"2025-11-13 05:05","pubTimestamp":1762981501,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251112:nPLXF51E2A:5","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ELVN","BK4007"],"gpt_icon":0},{"id":"2580223154","title":"Mizuho Securities Remains a Buy on Enliven Therapeutics (ELVN)","url":"https://stock-news.laohu8.com/highlight/detail?id=2580223154","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2580223154?lang=en_us&edition=fundamental","pubTime":"2025-11-04 05:05","pubTimestamp":1762203923,"startTime":"0","endTime":"0","summary":"Mizuho Securities analyst Salim Syed maintained a Buy rating on Enliven Therapeutics today and set a price target of $41.00. The company’s shares c...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/mizuho-securities-remains-a-buy-on-enliven-therapeutics-elvn-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/mizuho-securities-remains-a-buy-on-enliven-therapeutics-elvn-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","BK4139","BK4207","LENZ","BK4539","MFG","ELVN"],"gpt_icon":0},{"id":"2580242862","title":"Enliven Therapeutics Down Nearly 18%, on Pace for Largest Percent Decrease Since April 2022 -- Data Talk","url":"https://stock-news.laohu8.com/highlight/detail?id=2580242862","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2580242862?lang=en_us&edition=fundamental","pubTime":"2025-11-04 03:36","pubTimestamp":1762198560,"startTime":"0","endTime":"0","summary":"Enliven Therapeutics, Inc.  is currently at $19.27, down $4.15 or 17.72%. --Would be lowest close since Sept. 25, 2025, when it closed at $18.57. --On pace for largest percent decrease since April 5, 2022, when it fell 22.09%. --Currently down two consecutive days; down 19.61% over this period. --Down 14.36% year-to-date; on pace for worst year since 2023, when it fell 15.4%. --Down 91.22% from its all-time closing high of $219.48 on June 11, 2020. --Down 30.31% from 52 weeks ago , when it closed at $27.65. --Up 29.24% from its 52-week closing low of $14.91 on April 10, 2025. --Traded as low as $18.33; lowest intraday level since Sept. 26, 2025, when it hit $18.28. --Down 21.73% at today's intraday low; largest intraday percent decrease since April 5, 2022, when it fell as much as 37.42%","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LENZ","BK4539","BK4139","BK4007","ELVN"],"gpt_icon":0},{"id":"2580776241","title":"Promising Investment Opportunity: Enliven Therapeutics’ ELVN-001 Shows Strong Potential in CML Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2580776241","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2580776241?lang=en_us&edition=fundamental","pubTime":"2025-11-04 02:45","pubTimestamp":1762195515,"startTime":"0","endTime":"0","summary":"Analyst Sam Slutsky from LifeSci Capital maintained a Buy rating on Enliven Therapeutics and keeping the price target at $38.00. Sam Slutsky has gi...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/promising-investment-opportunity-enliven-therapeutics-elvn-001-shows-strong-potential-in-cml-treatment-ratings?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/promising-investment-opportunity-enliven-therapeutics-elvn-001-shows-strong-potential-in-cml-treatment-ratings?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","BK4139","LENZ","BK4539","ELVN"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.imaratx.com","stockEarnings":[{"period":"1week","weight":0.0006},{"period":"1month","weight":-0.2367},{"period":"3month","weight":-0.1102},{"period":"6month","weight":-0.208},{"period":"1year","weight":-0.2624},{"period":"ytd","weight":-0.2502}],"compareEarnings":[{"period":"1week","weight":-0.0017},{"period":"1month","weight":0.0271},{"period":"3month","weight":0.0254},{"period":"6month","weight":0.1452},{"period":"1year","weight":0.1612},{"period":"ytd","weight":0.1613}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. Its pipeline of small molecule kinase inhibitors include ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial has been activated to evaluate people with cancers harboring an abnormal HER2 gene. The company is based in Boulder, Colorado.","yearOnYearQuotes":[{"month":1,"riseRate":0.4,"avgChangeRate":-0.111243},{"month":2,"riseRate":0.6,"avgChangeRate":0.039232},{"month":3,"riseRate":0.6,"avgChangeRate":-0.005968},{"month":4,"riseRate":0.166667,"avgChangeRate":-0.083053},{"month":5,"riseRate":0.333333,"avgChangeRate":0.166061},{"month":6,"riseRate":0.833333,"avgChangeRate":0.03326},{"month":7,"riseRate":0.166667,"avgChangeRate":-0.105586},{"month":8,"riseRate":0.5,"avgChangeRate":-0.03666},{"month":9,"riseRate":0.5,"avgChangeRate":0.118476},{"month":10,"riseRate":0.5,"avgChangeRate":0.124766},{"month":11,"riseRate":0.166667,"avgChangeRate":0.036396},{"month":12,"riseRate":0.166667,"avgChangeRate":-0.096137}],"exchange":"NASDAQ","name":"Enliven Treateutics","nameEN":"Enliven Treateutics"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Enliven Treateutics(ELVN),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Enliven Treateutics(ELVN) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Enliven Treateutics,ELVN,Enliven Treateutics股票,Enliven Treateutics股票老虎,Enliven Treateutics股票老虎国际,Enliven Treateutics行情,Enliven Treateutics股票行情,Enliven Treateutics股价,Enliven Treateutics股市,Enliven Treateutics股票价格,Enliven Treateutics股票交易,Enliven Treateutics股票购买,Enliven Treateutics股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Enliven Treateutics(ELVN),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Enliven Treateutics(ELVN) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction